Mohammad A K Azad
Overview
Explore the profile of Mohammad A K Azad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
821
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thombare V, Swarbrick J, Azad M, Zhu Y, Lu J, Yu H, et al.
ACS Cent Sci
. 2024 Sep;
10(9):1703-1717.
PMID: 39345814
A significant increase in life-threatening infections caused by Gram-negative "superbugs" is a serious threat to global health. With a dearth of new antibiotics in the developmental pipeline, antibiotics with novel...
2.
Nang S, Lu J, Yu H, Wickremasinghe H, Azad M, Han M, et al.
Clin Microbiol Infect
. 2024 Mar;
30(6):787-794.
PMID: 38522841
Objectives: Bacteriophage (phage) therapy is a promising anti-infective option to combat antimicrobial resistance. However, the clinical utilization of phage therapy has been severely compromised by the potential emergence of phage...
3.
Li M, Azad M, Thompson P, Roberts K, Velkov T, Zhu Y, et al.
Antibiotics (Basel)
. 2023 Feb;
12(2).
PMID: 36830325
Polymyxins are last-line antibiotics for the treatment of Gram-negative 'superbugs'. However, nephrotoxicity can occur in up to 60% of patients administered intravenous polymyxins. The mechanisms underpinning nephrotoxicity remain unclear. To...
4.
Pathak V, Park H, Zemlyanov D, Bhujbal S, Ahmed M, Azad M, et al.
Pharm Res
. 2022 Aug;
39(11):2781-2799.
PMID: 35915320
Purpose: Tobramycin shows synergistic antibacterial activity with colistin and can reduce the toxic effects of colistin. The purpose of this study is to prepare pulmonary powder formulations containing both colistin...
5.
Lu J, Azad M, Moreau J, Zhu Y, Jiang X, Tonta M, et al.
Cell Mol Life Sci
. 2022 May;
79(6):296.
PMID: 35570209
Polymyxin antibiotics are often used as a last-line defense to treat life-threatening Gram-negative pathogens. However, polymyxin-induced kidney toxicity is a dose-limiting factor of paramount importance and can lead to suboptimal...
6.
Patil N, Thombare V, Li R, He X, Lu J, Yu H, et al.
Front Chem
. 2022 Apr;
10:843163.
PMID: 35372270
Peptide-Peptide Nucleic Acid (PNA) conjugates targeting essential bacterial genes have shown significant potential in developing novel antisense antimicrobials. The majority of efforts in this area are focused on identifying different...
7.
Roberts K, Zhu Y, Azad M, Han M, Wang J, Wang L, et al.
Nat Commun
. 2022 Mar;
13(1):1625.
PMID: 35338128
The emergence of multidrug-resistant (MDR) Gram-negative pathogens is an urgent global medical challenge. The old polymyxin lipopeptide antibiotics (polymyxin B and colistin) are often the only therapeutic option due to...
8.
Li M, Azad M, Ahmed M, Zhu Y, Song J, Zhou F, et al.
Antibiotics (Basel)
. 2022 Mar;
11(3).
PMID: 35326770
Inhaled polymyxins are increasingly used to treat pulmonary infections caused by multidrug-resistant Gram-negative pathogens. We have previously shown that apoptotic pathways, autophagy and oxidative stress are involved in polymyxin-induced toxicity...
9.
Kho Z, Azad M, Han M, Zhu Y, Huang C, Schittenhelm R, et al.
PLoS Pathog
. 2022 Mar;
18(3):e1010308.
PMID: 35231068
The opportunistic pathogen Acinetobacter baumannii possesses stress tolerance strategies against host innate immunity and antibiotic killing. However, how the host-pathogen-antibiotic interaction affects the overall molecular regulation of bacterial pathogenesis and...
10.
Jiang X, Patil N, Azad M, Wickremasinghe H, Yu H, Zhao J, et al.
Chem Sci
. 2021 Oct;
12(36):12211-12220.
PMID: 34667587
Multidrug-resistant Gram-negative bacteria represent a major medical challenge worldwide. New antibiotics are desperately required with 'old' polymyxins often being the only available therapeutic option. Here, we systematically investigated the structure-activity...